![](https://ltrpharma.com/wp-content/uploads/2024/07/Ausbiz-300x300.png)
Ausbiz | Interview with Lee Rodne
Following this week’s announcement of a successful $10.5M capital raise, LTR Pharma’s Executive Chairman, Lee Rodne, spoke with ausbiz about future plans for the commercial
LTR Pharma has officially debuted on the Australian Securities Exchange (ASX) under ticker code LTP.
Our foremost priority is to execute a bioequivalence trial of SPONTAN® to support expedited regulatory approvals, and to market and sell SPONTAN in the United States and Australia, first.
We have a highly experienced team of pharmaceutical developers and commercialisation experts driving this program forward – and valued investors backing us too.
Successful phase I human proof of concept study now complete. SPONTAN® has shown to be six times faster than oral PDE5 inhibitors.
On track to register the first PDE5 inhibitor nasal spray, in a market estimated to reach US$6.0B in 2028.
Progressing to bioequivalence study, with expedited regulatory filings in the United States and Australia within 1-2 years.
View our Shareholder Communications summary here
View our Corporate Directory here
Following this week’s announcement of a successful $10.5M capital raise, LTR Pharma’s Executive Chairman, Lee Rodne, spoke with ausbiz about future plans for the commercial
In an interview with Stockhead‘s Sarah Hughan, LTR Pharma Executive Chairman Lee Rodne spoke of the Company’s successful $10.5 million capital raise, and how the
LTR Pharma’s A$10.5 million share placement has been featured in The Australian Business Review. Click to read the article.
9/204 Alice Street, Brisbane QLD 4000
Phone: 1800 519 711